The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity. The Secondary Objective: To assess the impact of these therapies on weight management practices and metabolic health.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in self-reported pain levels in participants microdosing GLP1s
Timeframe: 6 months
Concentration of complete blood cells, as a measure of immunological health, in participants microdosing GLP1s
Timeframe: 6 months
Concentration of basic metabolites (cholesterol, glucose, creatinine, sodium, potassium), as a measure of immunological health, in participants microdosing GLP1s
Timeframe: 6 months
Change in mood in participants microdosing GLP1s
Timeframe: 6 months
Change in heart rate variability in participants microdosing GLP1s
Timeframe: 6 months
Changes in sleep patterns in participants microdosing GLP1s
Timeframe: 6 months
Change in frequency of physical activity in participants microdosing GLP1s
Timeframe: 6 months
Change in frequency of physical activity in participants microdosing GLP1s
Timeframe: 6 months